EP2576787B1 - Mit polyzystischem ovarialsyndrom assoziierte snps, chips damit und ihre verwendung - Google Patents
Mit polyzystischem ovarialsyndrom assoziierte snps, chips damit und ihre verwendung Download PDFInfo
- Publication number
- EP2576787B1 EP2576787B1 EP10852344.0A EP10852344A EP2576787B1 EP 2576787 B1 EP2576787 B1 EP 2576787B1 EP 10852344 A EP10852344 A EP 10852344A EP 2576787 B1 EP2576787 B1 EP 2576787B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pcos
- dna
- artificial
- thada
- snps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Not-in-force
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Definitions
- This invention relates to SNPs associated with Polycystic Ovary Syndrome, chips comprising the same and the use thereof.
- Polycystic ovary syndrome is a clinical condition characterized by presence of two or more of these features: chronic oligo-ovulation or anovulation, androgen excess and polycystic ovaries. 1 As the most common cause of anovulatory infertility, PCOS affects 6-8% childbearing-aged women. 2,3 Additionally, PCOS is associated with important endocrine-metabolic derangements and a broad range of adverse sequelae, including dyslipidemia, atherosclerosis, insulin resistance and type 2 diabetes. 4-6 Insulin resistance is present in perhaps 50% of women with PCOS. 7 Among women with impaired glucose tolerance (IGT) and diabetes mellitus, about 20% were recognized at younger age to have PCOS. 8-10
- PCOS polycystic ovary syndrome
- An in vitro assay method and assay device for the diagnosis of the presence or the predisposition to suffer from PCOS and/or cardiovascular risk factors including: general obesity, abdominal obesity, hypertension, glucose intolerance, diabetes, hyperinsulinemia, general hypercholesterolemia, hypercholesterolemia with high LDL-cholesterol levels, low HDL-cholesterol levels and hypertriglyceridemia, as well as the grouping of some of these cardiovascular risk factors known as metabolic syndrome.
- the method and the kit are characterized in that they are based on the detection of at least one genotype or haplotype of a polymorphism in the CAPN5 gene selected from: Nt g.86 A>G Nt g.344 G>A, Nt c.1320 C>T and Nt c. 1469 G>A or combinations thereof.
- KR20040074800-A - discloses a composition for diagnosis of polycystic ovary syndrome comprising primers detecting single nucleotide polymorphism at 677th nucleotide of 5,10-methylenetetrahydrofolate reductase gene is provided, thereby improving accuracy of diagnosis of polycystic ovary syndrome.
- the single nucleotide polymorphism at 677th nucleotide of MTHFR gene is selected from cytosine/cytosine(C/C), cytosine/thymine(C/T) and thymine/thymine(T/T).
- Array based whole genome single-nucleotide polymorphisms (SNPs) association analyses may instead provide a comprehensive, unbiased approach to screen large scale patients to detect susceptibility genes for the diseases.
- SNPs whole genome single-nucleotide polymorphisms
- LHCGR encodes a G-protein coupled receptor for luteinizing hormone ( LH ) and choriogonadotropin ( HCG ).
- LH luteinizing hormone
- HCG choriogonadotropin
- LHCGR is expressed in granulosa cells at the later stages of preovulatory follicles.
- the induction of LHCGR during granulosa cell differentiation allows the preovulatory follicle to respond to the mid-cycle surge of LH, resulting in ovulation and release of the mature oocyte.
- inactivating (or loss-of-function) mutations of LHCGR are associated with increased LH, enlarged ovaries, oligomenorrhea, resistance to LH or HCG and infertility; 23,24 whereas activating mutations in affected women produce hyperandrogenism but no other effect on reproductive abnormalities. 25
- THADA peroxisome proliferator-activated receptor gamma
- THADA The function of THADA has not been well-characterized, but some evidence suggests it might be involved in the death receptor pathway and apoptosis. 32 THADA is extensively expressed in all tissues, and particularly high in lymphocytes, natural killer cells and monocytes. This suggests a role for THADA in the immune response. In the innate and/or adaptive immune response, THADA may participate as a cytokine in the inflammatory signaling pathway causing systemic diseases like PCOS.
- DENND1A the other associated 9q33.3 gene, encodes a DENN (differentially expressed in normal and neoplastic cells) domain that can hybridize with type-1 tumor necrosis factor receptor (TNFR1 ) as a negative regulator through a death domain-death domain interaction.
- TNFR1 type-1 tumor necrosis factor receptor
- DENND1A cannot repress normally, resulting in elevated TNFR1 that further contributes to the induction of apoptosis and activation of the inflammation pathway.
- THADA and DENND1A seem to play roles in PCOS through a chronic inflammation pathogenesis.
- CRP C-reactive protein
- PAI-1 plasminogen activator inhibitor-1
- the present invention provides THADA, LHCGR and DENND1A genes with SNPs, wherein THADA gene with one or more SNPs of rs11891936 (A/G), rs17030684 (T/C), rs4340576 (G/A), rs12468394 (A/C), rs7567607 (A/G), rs13429458 (C/A), rs7568365(T/C), rs7582497 (G/A), rs10176241 (G/A), rs6744642 (T/C), rs12478601 (T/C), rs1038822(C/T), rs7559891 (A/G), rs1873555 (G/A), rs7596052 (A/G), rs10165527 (A/G), rs6726014 (T/A), rs2374551 (G/C),
- (M/N) means minor allele/ major allele in the SNP.
- the present invention further provides an entire set of probes according to claim 1 and its use according to claim 2.
- the present invention further provides a method according to claim 3 wherein, this method mainly comprises the following steps: extracting the peripheral blood DNA from patients and hybridizing with the entire set of probes of claim 1; scanning and analyzing the results with the associated SNP allele information to predict the risk of PCOS.
- PCOS cases All affected individuals defined as PCOS cases were diagnosed according to the Revised 2003 Consensus on Diagnostic Criteria and Long-term Health Risks Related to Polycystic Ovary Syndrome 1 , i.e., any two of the following three criteria: oligo- or anovulation, clinical and/or biochemical signs of hyperandrogenism and polycystic ovary morphology. Patients with other causes of oligomenorrhea or hyperandrogenism were excluded. Clinical information was collected from the cases through a full clinical checkup by physician specialists. Additional demographic information was collected from both cases and controls through a structured questionnaire. All participants provided written informed consents. The study was approved by the Institutional Ethical Committee of each hospital and was conducted according to Declaration of Helsinki principles.
- Genome-wide genotyping was performed using the Affymetrix Genome-Wide Human SNP Array 6.0. Quality control filtering of the GWAS data was performed as follows: the arrays whose Contrast QC was 0.4 or greater being left out of further data analysis. Genotype data were generated using the birdseed algorithm. For sample filtering, array with generated genotypes of fewer than 95% of loci were excluded. For SNP filtering (after sample filtering), SNP with call rates ⁇ 95% in either case or control samples were removed. SNPs whose MAF (minor allele frequency) was ⁇ 1%, or deviated significantly from Hardy Weinberg Equilibrium (HWE, P ⁇ 0.001) in controls were excluded. A total of 649,264 SNPs passed the quality criteria and were used for the subsequence analysis.
- HWE Hardy Weinberg Equilibrium
- Allele-specific oligonucleotides to the SNP sequences are printed on epoxy-coated glass microscope slide using a microarray printer. Each set was printed in duplicate so that for each SNP there were four major and minor allele oligonucleotide spots. Twelve such blocks of oligonucleotides were printed on each slide thereby allowing the testing of DNAs from twelve different people per slide.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (4)
- Vollständiger Satz von Proben mit SNPs, die zur Prognose der Gefahr des polyzystischen Ovarialsyndroms verwendet werden, wobei die Nukleotidsequenzen der Proben durch Seq. ID Nr. 1-56 dargestellt werden.
- Verwendung des vollständigen Satzes von Proben nach Anspruch 1 bei der Prognose der Gefahr des polyzystischen Ovarialsyndroms.
- Verfahren zur Prognose der Gefahr des polyzystischen Ovarialsyndroms, wobei das Verfahren den vollständigen Satz von Proben nach Anspruch 1 verwendet.
- Verfahren nach Anspruch 3, wobei das Verfahren in erster Linie die folgenden Schritte umfasst:Extrahieren der peripheren Blut-DNA der Patienten und Hybridisieren mit dem vollständigen Satz von Proben nach Anspruch 1; Scannen und Analysieren der Ergebnisse mit der assoziierten SNP-Allel-Information zur Prognose der Gefahr des polyzystischen Ovarialsyndroms.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2010/073387 WO2011150545A1 (en) | 2010-05-31 | 2010-05-31 | Snps associated with polycystic ovary syndrome, chips comprising the same and use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2576787A4 EP2576787A4 (de) | 2013-04-10 |
EP2576787A1 EP2576787A1 (de) | 2013-04-10 |
EP2576787B1 true EP2576787B1 (de) | 2017-05-03 |
Family
ID=45066105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10852344.0A Not-in-force EP2576787B1 (de) | 2010-05-31 | 2010-05-31 | Mit polyzystischem ovarialsyndrom assoziierte snps, chips damit und ihre verwendung |
Country Status (4)
Country | Link |
---|---|
US (1) | US8685647B2 (de) |
EP (1) | EP2576787B1 (de) |
CN (1) | CN102918158B (de) |
WO (1) | WO2011150545A1 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2757942T3 (es) * | 2012-05-21 | 2020-04-30 | Penn State Res Found | Composiciones y métodos relacionados con la variante 2 de dennd1a y síndrome de ovario poliquístico |
CN104411824B (zh) * | 2012-06-18 | 2017-12-26 | 山东大学 | 与多囊卵巢综合征相关的snp标记 |
EP4286517A3 (de) | 2013-04-04 | 2024-03-13 | President and Fellows of Harvard College | Therapeutische verwendungen einer genomänderung mit crispr-/cas-systemen |
WO2015077265A1 (en) | 2013-11-19 | 2015-05-28 | Virginia Commonwealth University | Compositions and methods for prophylaxis and/or therapy of disorders that correlate with dennd1a variant 2 |
CN104777242B (zh) * | 2014-01-14 | 2016-08-17 | 中国科学院大连化学物理研究所 | 用于诊断多囊卵巢综合征的联合标志物、试剂盒和系统 |
CN104593513A (zh) * | 2015-02-06 | 2015-05-06 | 上海中优医药高科技有限公司 | 一种卵巢反应相关基因的基因检测方法 |
JP6602847B2 (ja) | 2015-03-27 | 2019-11-06 | 株式会社ボナック | デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子 |
CN107847524A (zh) | 2015-03-27 | 2018-03-27 | 哈佛学院校长同事会 | 经过修饰的t细胞及其制备和使用方法 |
WO2018195129A1 (en) | 2017-04-17 | 2018-10-25 | University Of Maryland, College Park | Embryonic cell cultures and methods of using the same |
CN109022565B (zh) * | 2017-06-12 | 2022-02-11 | 山大生殖研发中心有限公司 | 多囊卵巢综合征的microRNA生物标记物和其应用 |
CN107190076B (zh) * | 2017-06-28 | 2019-12-27 | 中国科学院苏州生物医学工程技术研究所 | 一种人肿瘤相关的甲基化位点及其筛选方法和用途 |
CN113049838A (zh) * | 2019-12-27 | 2021-06-29 | 山东大学 | 多囊卵巢形态阈值和其在诊断多囊卵巢综合征中的应用 |
CN115364219A (zh) * | 2021-12-02 | 2022-11-22 | 山东大学 | Thada在制备糖代谢紊乱疾病预防及治疗药物中的应用 |
CN115372626A (zh) * | 2022-07-12 | 2022-11-22 | 山东大学 | Thada在制备糖代谢紊乱疾病筛选试剂中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100504002B1 (ko) * | 2003-02-19 | 2005-07-27 | 이수만 | 메틸렌테트라하이드로폴레이트 환원효소 유전자의 677번뉴클레오티드 위치의 단일 염기 다형성을 검출할 수 있는프라이머를 포함하는 다낭성 난포 증후군 진단용 조성물 |
WO2005116247A1 (es) * | 2004-05-27 | 2005-12-08 | Neocodex | Método y dispositivo de detección in vitro del síndrome de ovario poliquístico (pcos) y de patologías que suponen riesgo cardiovascular |
CA2609229A1 (en) * | 2005-05-23 | 2006-11-30 | Universiteit Maastricht | Genetic association of polymorphisms in the atf6-alpha gene with insulin resistance phenotypes |
US8575120B2 (en) * | 2007-03-13 | 2013-11-05 | The Children's Hospital Of Philadelphia | Genetic alterations on chromosome 12 and methods of use thereof for the diagnosis and treatment of type 1 diabetes |
US20110294680A1 (en) * | 2008-02-22 | 2011-12-01 | Duke University | Methods and compositions for predicting success in addictive substance cessation and for predicting a risk of addiction |
-
2010
- 2010-05-31 CN CN201080067164.6A patent/CN102918158B/zh active Active
- 2010-05-31 EP EP10852344.0A patent/EP2576787B1/de not_active Not-in-force
- 2010-05-31 WO PCT/CN2010/073387 patent/WO2011150545A1/en active Application Filing
-
2012
- 2012-06-18 US US13/525,774 patent/US8685647B2/en active Active
Non-Patent Citations (1)
Title |
---|
AFFYMETRIX: "Data Sheet Affymetrix(R) Genome-Wide Human SNP Array 6.0", INTERNET CITATION, 2007, pages 1 - 4, XP002525407, Retrieved from the Internet <URL:http://www.affymetrix.com/support/technical/datasheets/genomewide_snp6_datasheet.pdf> [retrieved on 20090410] * |
Also Published As
Publication number | Publication date |
---|---|
US8685647B2 (en) | 2014-04-01 |
WO2011150545A1 (en) | 2011-12-08 |
US20120309642A1 (en) | 2012-12-06 |
CN102918158A (zh) | 2013-02-06 |
EP2576787A4 (de) | 2013-04-10 |
CN102918158B (zh) | 2014-05-28 |
EP2576787A1 (de) | 2013-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2576787B1 (de) | Mit polyzystischem ovarialsyndrom assoziierte snps, chips damit und ihre verwendung | |
Craig et al. | Retinol binding protein 4 as a candidate gene for type 2 diabetes and prediabetic intermediate traits | |
Sladek et al. | A genome-wide association study identifies novel risk loci for type 2 diabetes | |
Pappa et al. | Gestational diabetes mellitus shares polymorphisms of genes associated with insulin resistance and type 2 diabetes in the Greek population | |
Horikawa et al. | Genetic variations in calpain-10 gene are not a major factor in the occurrence of type 2 diabetes in Japanese | |
Hester et al. | Implication of European-derived adiposity loci in African Americans | |
Joy et al. | Genetics of metabolic syndrome | |
Alharbi et al. | Insulin receptor substrate-1 (IRS-1) Gly927Arg: correlation with gestational diabetes mellitus in Saudi women | |
Jenkinson et al. | Association of dopamine D2 receptor polymorphisms Ser311Cys and TaqIA with obesity or type 2 diabetes mellitus in Pima Indians | |
Hussain et al. | TCF7L2 rs7903146 polymorphism and diabetic nephropathy association is not independent of type 2 diabetes—a study in a south Indian population and meta-analysis | |
Ilie | Advances in PCOS Pathogenesis and progression—mitochondrial mutations and dysfunction | |
Saxena et al. | Polycystic ovary syndrome is not associated with genetic variants that mark risk of type 2 diabetes | |
Jones et al. | Metabolic and cardiovascular genes in polycystic ovary syndrome: a candidate-wide association study (CWAS) | |
Aslibekyan et al. | Preliminary evidence of genetic determinants of adiponectin response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network | |
Li et al. | Molecular genetics of polycystic ovary syndrome: an update | |
Sanchez-Corona et al. | Polymorphisms in candidate genes for type 2 diabetes mellitus in a Mexican population with metabolic syndrome findings | |
Schallschmidt et al. | Two novel candidate genes for insulin secretion identified by comparative genomics of multiple backcross mouse populations | |
Adamska et al. | The type 2 diabetes susceptibility TCF7L2 gene variants affect postprandial glucose and fat utilization in non-diabetic subjects | |
Caro-Gomez et al. | Association of Native American ancestry and common variants in ACE, ADIPOR2, MTNR1B, GCK, TCF7L2 and FTO genes with glycemic traits in Colombian population | |
Beckers et al. | Replication of the SH2B1 rs7498665 association with obesity in a Belgian study population | |
Saad et al. | Leptin receptor gene polymorphisms c. 668A> G and c. 1968G> C in Sudanese women with preeclampsia: a case-control study | |
Sayad et al. | Genetic susceptibility for periodontitis with special focus on immune-related genes: A concise review | |
Chioza et al. | Genome wide high density SNP-based linkage analysis of childhood absence epilepsy identifies a susceptibility locus on chromosome 3p23-p14 | |
Hirai et al. | WRN gene 1367 Arg allele protects against development of type 2 diabetes mellitus | |
Sun et al. | Novel SNPs of WNK1 and AKR1C3 are associated with preeclampsia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20121116 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20130307 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20140410 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150324 |
|
INTC | Intention to grant announced (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20161122 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 890023 Country of ref document: AT Kind code of ref document: T Effective date: 20170515 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602010042136 Country of ref document: DE |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20170628 Year of fee payment: 8 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20170503 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 890023 Country of ref document: AT Kind code of ref document: T Effective date: 20170503 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170804 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170803 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170903 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170803 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602010042136 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170531 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170531 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170531 |
|
26N | No opposition filed |
Effective date: 20180206 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20170531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171201 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170531 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20180416 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170531 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170703 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170531 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20180531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20100531 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170503 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170503 |